Investigational Studies

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/drugs-in-the-pipeline/cannabidiol-gets-orphan-drug-status-for-preventing-ischemia-reperfusion-injury/

by

Novelion Therapeutics Inc. (NASDAQ:NVLN) and Intec Pharma Ltd. (NASDAQ:NTEC), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation of the two firms. Earnings and Valuation Demonstrates Novelion Therapeutics Inc. and Intec Pharma Ltd. earnings per share […]

by

Home  » eNewsletter FSM eDigest | March 6, 2018 Medical Foods – Insights Into FDA’s Interpretation and Enforcement By Elizabeth Campbell and Allen Sayler “Medical food” is a commonly misunderstood term, as it is used by the industry for the U.S. Food and Drug Administration (FDA)’s regulated products. Many manufacturers find marketing products as medical foods […]

by

SEATTLE, Feb. 20, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Cardiol Therapeutics (TSX: CRDL) (OTC: CRTPF) and its development of cannabidiol (CBD) based drugs for the treatment of heart failure. […]

by

Infantile spasm treatment play a major role in modern healthcare, as they are used for the treatment of seizures of an epilepsy syndrome in infants usually below 1 year.   The global infantile spasm treatment market size was valued at US$ 111.1 million in 2017 and is expected to exhibit a CAGR of 3.1% over […]

by

In new studies conducted at UC San Francisco, a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new […]

by

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/drugs-in-the-pipeline/cannabinoid-based-tx-gets-orphan-drug-designation-for-autoimmune-hepatitis/

by

  References   1. FDA, “Statement from FDA Commissioner Scott Gottlieb, M.D., on Proposed Modernization of FDA’s Drug Review Office,” Statement, June 4, 2018. 2. FDA, “Statement from FDA Commissioner Scott Gottlieb, M.D., on New Agency Efforts to Advance the Patient Voice in Medical Product Development and FDA Regulatory Decision-Making,” Statement, June 12, 2018. 3. […]

by

A request for a potential cannabis-based treatment for multiple sclerosis to be given Fast Track designation, speeding its development as it readies to enter clinical testing, is now before the U.S. Food and Drug Administration (FDA), MMJ International Holdings announced. MMJ-001, as this lead candidate is known, aims to treat the spasticity (muscle stiffness) associated with progressive multiple sclerosis. The company is also targeting Huntington’s-associated chorea, […]

by

DUBLIN–(Business Wire)–The “Global Dravet Syndrome Market: Industry Analysis Outlook (2019-2023)” report has been added to ResearchAndMarkets.com’s offering. The disorder is considered orphan indication, and there are very limited treatment options available in the market. However, several therapeutics for Dravet syndrome are in pipeline. The drugs in development are getting orphan drug designation by FDA and […]

by